Tag Archives: Bortezomib

Concomitant administration of bortezomib with powerful CYP3A4

Background and Objective: Bortezomib, an antineoplastic agent with proteasome inhibitory activity, is extensively metabolized by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C19. Drugs that affect these enzymes might hence have an impact on the pharmacological profile of … Continue reading

Posted in Uncategorized | Tagged | Leave a comment